Industry news that matters to you.  Learn more

Quanterix Marks Leadership in Accelerating Neurology Research with 100-Publication Milestone

Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, recently announced it has surpassed an important milestone that its technology has been highlighted in more than 100 third-party, peer-reviewed publications in neurology. Driven by increased demand for the company’s Simoa technology, which continues to prove itself as the industry standard for ultra-sensitive biomarker detection, this brings the total number of publications for the company to over 215 across neurology, oncology, cardiology, inflammation and infectious disease.

Quanterix’s Single Molecule Array Technology Unlocks New Biomarker Fueling Advancements in Neurological Research

Quanterix Corporation, a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, recently announced that its Single Molecule Array technology (Simoa) was prominently featured in three recently published research papers, highlighting applications for a promising new brain biomarker never before measured in blood, referred to as neurofilament light (NFL), which was shown to be indicative of neuronal injury.

Quanterix Announces the Simoa Accelerator, an Innovation Center for Biomarker Research and Custom Assay Development

Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, recently announced the opening of The Simoa Accelerator, a dedicated laboratory environment for custom assay development and clinical sample testing. Designed to provide access to the revolutionary Single Molecule Array (Simoa) HD-1 Analyzer, this state-of-the-art facility allows users to experience the advantages of the technology firsthand.